Hengenix Biotech, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2010-01-01
- Employees
- 51
- Market Cap
- -
- Website
- https://hengenix.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Hengenix Biotech Inc
- Target Recruit Count
- 32
- Registration Number
- NCT04583228
- Locations
- 🇺🇸
Frontage Clinical Services, Inc., Secaucus, New Jersey, United States
Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Hengenix Biotech Inc
- Registration Number
- NCT04561076
News
No news found